Sun Pharma Advanced Research Company Limited has informed the Exchange about Investor Presentation
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SPARC held an R&D Day investor presentation on January 8, 2026 at 4:00 PM IST, outlining a streamlined, thematically cohesive drug development portfolio. The company highlighted three core focus areas: Antibody Drug Conjugates (ADCs) including bi-specific targeting and immune-stimulating antibody conjugates, cancer therapeutics centered on DDR pathway inhibitors for synthetic lethality, and topical alternatives to standard-of-care treatments in dermatology and autoimmune diseases. Key clinical programs discussed include SCD-153, a first-in-class topical drug for Alopecia Areata, with Phase 1b interim readout expected in Q4 2026 and Phase 2 IND filing planned for Q2 2027. Another lead program, SBO-154 (an Anti-MUC1 ADC), is slated for Phase 1b initiation in Q2 2026 with preliminary clinical proof-of-concept data expected by Q2 2027.
This is an R&D-focused pharma company sharing pipeline updates and clinical timelines rather than financial guidance, so near-term stock impact may be limited. However, the multi-year milestones and upcoming data readouts could serve as future catalysts for investor sentiment.